The vaccine targets outer membrane vesicles that are common to both Neisseria meningitidis and Neisseria gonorrhoeae.
Gonorrhea infections in China are showing decreasing susceptibility to ceftriaxone along with high levels of resistance to other antibiotics.
The designation means that the NgG vaccine, which is in a phase 2 trial, will receive expedited review by FDA officials.
Analysis of Neisseria gonorrhoeae isolates from 3 African countries finds high resistance to ciprofloxacin and emerging resistance determinants for azithromycin.
The trial is evaluating the efficacy of oral zoliflodacin compared with the standard regimen of ceftriaxone plus azithromycin.
State health officials say the strain, which had reduced susceptibility to the last remaining recommended antibiotic treatment, is a serious public health concern.
International travel may play a critical role in the spread of multidrug-resistant (MDR) sexually transmitted infections (STIs), according to a study published late last week in Travel Medicine and Infectious Disease.
Researchers in Austria are reporting the identification of a second strain of extensively drug-resistant (XDR) gonorrhea.
The World Health Organization (WHO) today issued a report highlighting the threat of healthcare-associated infections (HAIs) and the role that infection prevention and control (IPC) programs can play in reducing that threat.
Data suggest 4CMenB protection against gonorrhea and support the feasibility of a gonococcal vaccine.
